PAVmed Inc. [NASDAQ: PAVM] closed the trading session at $6.53 on 06/17/21. The day’s price range saw the stock hit a low of $6.05, while the highest price level was $6.585. The company report on June 14, 2021 that Tim Baxter, Former CEO of Samsung Electronics North America and Global Technology Industry Leader, Joins PAVmed Board of Directors.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, announced the appointment of prominent global technology industry leader Tim Baxter, to its Board of Directors. Mr. Baxter will serve as Chair of the Company’s Nomination Committee and as a member of its Audit Committee.
“I am very pleased to welcome Tim Baxter to PAVmed’s Board of Directors,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief Executive Officer. “Mr. Baxter is among the most accomplished and respected executives in the technology industry. His long and distinguished career as a senior global executive at AT&T, Sony and, most recently, at Samsung Electronics, where he was President and CEO, have kept him at the frontlines of technological innovation for over three decades. He shares our passion for leveraging technology in the service of society and has championed the same culture of trust and shared success we have built at PAVmed.”.
The stocks have a year to date performance of 208.02 percent and weekly performance of 12.20 percent. The stock has been moved at 245.50 percent over the last six months. The stock has performed 54.74 percent around the most recent 30 days and changed 52.57 percent over the most recent 3-months.
If compared to the average trading volume of 3.23M shares, PAVM reached to a volume of 2393841 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PAVmed Inc. [PAVM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PAVM shares is $8.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PAVM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for PAVmed Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 30, 2021. While these analysts kept the previous recommendation, Ascendiant Capital Markets raised their target price to Buy. The new note on the price target was released on November 05, 2020, representing the official price target for PAVmed Inc. stock. Previously, the target price had yet another raise to $5, while Maxim Group analysts kept a Buy rating on PAVM stock.
The Average True Range (ATR) for PAVmed Inc. is set at 0.37 The Price to Book ratio for the last quarter was 10.20, with the Price to Cash per share for the same quarter was set at 0.59.
PAVM stock trade performance evaluation
PAVmed Inc. [PAVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.20. With this latest performance, PAVM shares gained by 54.74% in over the last four-week period, additionally plugging by 245.50% over the last 6 months – not to mention a rise of 173.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PAVM stock in for the last two-week period is set at 72.91, with the RSI for the last a single of trading hit 78.00, and the three-weeks RSI is set at 68.29 for PAVmed Inc. [PAVM]. The present Moving Average for the last 50 days of trading for this stock 4.99, while it was recorded at 6.08 for the last single week of trading, and 3.18 for the last 200 days.
PAVmed Inc. [PAVM]: An insightful look at the core fundamentals
Return on Total Capital for PAVM is now -259.63, given the latest momentum, and Return on Invested Capital for the company is -582.82. When it comes to the capital structure of this company, PAVmed Inc. [PAVM] has a Total Debt to Total Equity ratio set at 789.03. Additionally, PAVM Total Debt to Total Capital is recorded at 88.75, with Total Debt to Total Assets ending up at 75.64.
Reflecting on the efficiency of the workforce at the company, PAVmed Inc. [PAVM] managed to generate an average of -$1,371,040 per employee.PAVmed Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.20 and a Current Ratio set at 15.20.
Earnings per share (EPS) analysis for PAVmed Inc. [PAVM] stock
With the latest financial reports released by the company, PAVmed Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -30.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PAVM.
PAVmed Inc. [PAVM]: Insider Ownership positions
There are presently around $118 million, or 21.70% of PAVM stock, in the hands of institutional investors. The top three institutional holders of PAVM stocks are: BLACKROCK INC. with ownership of 4,354,014, which is approximately 135.578% of the company’s market cap and around 2.60% of the total institutional ownership; VANGUARD GROUP INC, holding 3,462,716 shares of the stock with an approximate value of $22.61 million in PAVM stocks shares; and FMR LLC, currently with $9.14 million in PAVM stock with ownership of nearly New of the company’s market capitalization.
Positions in PAVmed Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 71 institutional holders increased their position in PAVmed Inc. [NASDAQ:PAVM] by around 9,970,293 shares. Additionally, 20 investors decreased positions by around 771,945 shares, while 10 investors held positions by with 7,387,183 shares. The mentioned changes placed institutional holdings at 18,129,421 shares, according to the latest SEC report filing. PAVM stock had 35 new institutional investments in for a total of 4,374,717 shares, while 10 institutional investors sold positions of 212,478 shares during the same period.